NCT06473844 Efficacy of SGLT2 Inhibitors in Adults With Sepsis
| NCT ID | NCT06473844 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Authority, Hong Kong |
| Condition | Sepsis |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-03-05 |
| Primary Completion | 2027-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-03-05 with a primary completion date of 2027-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Goal of this clinical trial is to examine the safety and efficacy of SGLT2 inhibitors on the clinical outcomes in patients with sepsis. Main study outcomes are as follows: (i) Primary objective is to examine the efficacy and safety of SGLT2 inhibitors on clinical outcomes in patients with sepsis. (ii) Secondary objective is to examine the effect of SGLT2 inhibitors on inflammatory markers in patients with sepsis.
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or above * New onset of sepsis within 48 hours defined according to the Sepsis-3 criteria. (≥2 SOFA) * Provision of signed and dated informed consent form from participant or surrogate * Ability to take and adhere to oral and enteral medication regimen * Willingness to comply Exclusion Criteria: * Current or recent use of SGLT2 inhibitors (within 12wks prior to randomization) * Impaired renal function * Clinically unstable or in refractory hypotension * History of ketoacidosis * Gastrointestinal surgery or GI absorption / malabsorption disorder * Pregnancy * Known allergic or hypersensitivity reactions to any SGLT2 inhibitors * Treatment with another investigational drug or other interventions within 30 days prior to trial
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06473844 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06473844 currently recruiting?
Yes, NCT06473844 is actively recruiting participants. Contact the research team at pyeungng@hku.hk for enrollment information.
Where is the NCT06473844 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong, Hong Kong, Hong Kong, Hong Kong, Hong Kong.
Who is sponsoring the NCT06473844 clinical trial?
NCT06473844 is sponsored by Hospital Authority, Hong Kong. The trial plans to enroll 60 participants.